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Does low intensity pulsed ultrasound (LIPUS) accelerate
recovery in adults and children who have experienced bone
fractures or osteotomy (cutting of a bone)? An expert panel
rapidly produced these recommendations based on a linked
systematic review triggered by a large multicentre
randomised trial in adults with tibial fracture.
Fracture is common (see box 1). Bones can also be broken for
medical reasons; osteotomy is a procedure whereby a bone is
cut to shorten, lengthen, or to change its alignment. Following
osteotomy, the bone has similar healing problems as traumatic
fractures, and may require more extensive recovery.1
Irrespective of age, location, andmechanism of the broken bone,
whether it is managed with or without surgery, and whether it
heals as expected or with delay, the idea of speeding or
enhancing this healing tominimise symptoms and inconvenience
for the patient is appealing. Bone stimulators such as LIPUS
and electromagnetic field therapy might promote bone healing
by stimulating bone growth (osteogenesis) in long or other
bones.
Guidance from independent organisations on use of LIPUS for
bone healing is scarce, but data suggest the device is commonly
used in clinical practice (box 1). Prices vary across countries,
each device costing between US$1300 and $5000 (based on US
and UK).
The TRUST randomised controlled trial published in The BMJ
on 25October 2016 found that the addition of LIPUS to standard
care in 501 adult patients undergoing surgery for fresh tibial
fracture did not improve functional recovery or accelerate
radiographic healing at one year follow up compared with a
sham device.9 The BMJRapid Recommendations team believed
that the TRUST trial, if considered in a new systematic review
and meta-analysis, could change practice. Previous systematic
reviews had concluded that potential benefits of LIPUS on bone
healing were highly uncertain, with calls for trials with
safeguards against bias and a focus on outcomes important to
patients.10 11The linked publications in this package (see “Linked
articles” box) synthesise the latest evidence and translate it for
clinical care.
The evidence
Evidence requested from the panel to inform recommendations:
• A new rapid systematic review of the effects of LIPUS
added to standard care for a variety of fractures and
osteotomies16
• A systematic literature search on patients’ values and
preferences, which did not identify any relevant studies
(see appendix 4 on bmj.com).
Systematic review of LIPUS for all fracture
healing
The data from the TRUST trial9 were included in a linked
systematic review of randomised trials of LIPUS compared with
sham device or no device on patient-important outcomes in
patients with a fracture or osteotomy. Fig 1⇓ shows details about
the trials and characteristics of included patients.16
We judged that the systematic review provides evidence of
moderate to high certainty that LIPUS has little or no impact
on time to return to work, time to full weight bearing, pain, the
number of subsequent operations, or time to radiographic healing
(see infographic). We were confident that there was little risk
of adverse events from the device, based on nine trials that
reported this outcome.
For return to work, time to full weight bearing, and number of
subsequent operations, our certainty in the evidence is moderate
(rather than high) because of imprecise estimates of effect, where
confidence intervals included potentially important benefit and
harm (see forest plots (figs 2-7) in the linked systematic
review).16The observed heterogeneity in the effect sizes between
trials for time to weight bearing, pain, and radiographic healing
was explained by considering risk of bias: studies with serious
methodological limitations due to lack of blinding (no use of
sham device) suggested a benefit, whereas studies without such
limitations did not (see subgroup analyses in the linked
systematic review).16 For these outcomes, we therefore based
our conclusions on the trials with low risk of bias. The estimates
for typical (prognostic) outcomes for patients not treated with
LIPUS were informed by the control arm of the TRUST trial,
which enrolled patients with tibia fractures in the US and Canada
and was at low risk of bias.
Understanding the recommendation
We unanimously agreed to issue a strong recommendation
against LIPUS for patients with any bone fractures or osteotomy.
We have moderate to high certainty of a lack of benefit for
outcomes important to patients, and, combined with the high
costs of treatment, LIPUS represents an inefficient use of limited
healthcare resources.
A particular challenge for the panel was to determine to what
extent the most trustworthy evidence—coming from trials of
This BMJ Rapid Recommendations article is one of a series that provides clinicians with trustworthy recommendations for potentially practice
changing evidence. BMJ Rapid Recommendations represent a collaborative effort between the MAGIC group (www.magicproject.org) and The
BMJ. A summary is offered here and the full version including decision aids is on the MAGICapp (www.magicapp.org), for all devices in multilayered
formats. Those reading and using these recommendations should consider individual patient circumstances and their values and preferences and
may want to use consultation decision aids in MAGICapp to facilitate shared decision making with patients. We encourage adaptation of
recommendations to allow contextualisation of recommendations and to reduce duplication of work. Those considering use or adaptation of content
may go to MAGICapp to link or extract its content or contact The BMJ for permission to reuse content in this article. Series adviser Rafael
Perera-Salazar.
Data supplements on bmj.com (see http://www.bmj.com/content/356/bmj.j576?tab=related#datasupp)
Infographic: Summary of recommendations and evidence
Appendix 1: Rapid Recommendation panel members
Appendix 2: Full list of authors’ declarations of interests
Appendix 3: Methodology for development of BMJ Rapid Recommendations
Appendix 4: Values and preferences search for literature
Appendix 5: The full information available on the MAGICapp
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What you need to know
• LIPUS is used for bone healing for people who have had fractures or osteotomy
• LIPUS is costly to purchase
• A new trial and linked systematic review provide moderate to high certainty evidence to support a strong recommendation against the
use of LIPUS for bone healing
• Further research is unlikely to alter the evidence
• Healthcare administrators and funders may consider de-implementation of LIPUS as a performance indicator in quality improvement
initiatives
Linked articles in this BMJ Rapid Recommendations cluster
• Schandelmaier S, Kaushal A, Lytvyn L, et al. Low intensity pulsed ultrasound for bone healing: systematic review of randomized
controlled trials. BMJ 2017;356:j656
Review of all available randomised trials that assessed LIPUS versus sham device or no device that informed the recommendation
made by the panel
• MAGICapp (www.magicapp.org)
Expanded version of the results with multilayered recommendations, evidence summaries, and decision aids for use on all devices
Box 1: Background information
Bone fracture
• More than one in three people have a fracture at some point in their life
• Each year around four per 100 people of all ages experience a fracture2
• Some 5-10% of these experience delayed healing or non-union of the fracture3
LIPUS
• Guidance
– 1994 US Food and Drug Administration (FDA) approved LIPUS for fracture healing and, in 2000, for treatment of established
non-unions4
– 2010 UK National Institute for Health and Care Excellence (NICE) issued a statement supporting the use of LIPUS to reduce fracture
healing time and to provide clinical benefit, particularly in circumstances of delayed healing and non-union5
• Data on use
– A Canadian survey of 450 trauma surgeons in 2008 found that nearly half of respondents were using bone stimulators to manage
tibial fractures. Of those, about half used electromagnetic field therapy and the other half used LIPUS6
– Global revenues for bone stimulators were about US$400m 2004.7 In 2007, sales from LIPUS were around $250m in the US8
– We found no data to describe whether use has changed over time
How the recommendation was created
Our international guideline panel included orthopaedic and musculoskeletal trauma surgeons, physiotherapists, general internists,
methodologists, and people with lived experience of bone fractures including one who used LIPUS (see appendix 1 on bmj.com for list of
panel members). No person had financial conflicts of interest; intellectual and professional conflicts were minimised and managed according
to BMJ Rapid Recommendations standards (see appendices 2 and 3 on bmj.com).
We followed the BMJ Rapid Recommendations procedures for creating a trustworthy recommendation.12 13 We discussed and agreed on
the clinical outcomes of most importance to patients and clinicians a priori, and the systematic review authors focused their reporting on
these. The outcomes chosen for LIPUS were:




The patient representatives judged radiographic healing as a less important outcome. It was included because many clinicians would consider
radiographic healing to inform their management decisions. Some patients may feel reassured by observing radiographic healing, with
increased confidence in resuming activities such as weight bearing and return to work.
Before seeing the evidence, we agreed on what would constitute an important benefit from using LIPUS for these outcomes, and how patient
values and preferences might vary between persons. Guided by patients on our panel, we agreed that most people want at least a possibly
important benefit in functional recovery time or pain to make the time and expense of using LIPUS worthwhile. Reduced adherence with the
device in the TRUST trial suggests that LIPUS can be burdensome to patients.9
We applied the GRADE system to critically appraise the evidence andmove from evidence to recommendations (appendix 3).14We considered
the balance of benefits, harms, and burdens of the procedure; the quality of evidence for each outcome; the typical and expected variation
in patient values and preferences; resources; feasibility; and acceptability—details of our reasoning are summarised in the infographic and
discussed further in the text.15Recommendations can be strong or weak, for or against a course of action. We place a low value on speculative
benefits of treatments. Thus, when available evidence suggests no benefit, or only very low quality evidence suggests benefit and moderate
or high quality evidence shows appreciable adverse effects, burden, or cost, the panel would make a strong recommendation against an
intervention.
patients with fresh tibial and clavicle fractures managed
operatively—could be applied to adults with different types of
fracture or osteotomies. Trials including patients with stress
fractures, non-union, and osteotomies were either at high risk
of bias or did not contribute sufficient outcome data to the
systematic review. After extensive deliberations, the panel found
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no compelling anatomical or physiological reasons why LIPUS
would probably be beneficial in these other patient populations.
For example, if LIPUS on fresh fractures does not decrease the
incidence of non-unions, it is unlikely to exert a beneficial effect
in the conversion of non-unions into healed bones. Furthermore,
osteotomies have the same biological response as for traumatic
fractures. An additional challenge faced by the panel was that
no trials included children. Paediatric fractures typically heal
faster and have lower rates of non-union; thus, any potential
benefit of LIPUS for children is likely to be even smaller than
that for adults. The panel concluded that the evidence was
applicable to all of these groups, and did not downgrade their
certainty in the evidence.20
In response to peer review comments, the panel again considered
the applicability to other fractures and populations, in particular
non-union fractures. Reviewers pointed to differing healing
methods in non-union, and the potential that smaller effect sizes
could make a difference to patients. Non-union is the result of
impaired bone health, as seen in smokers and diabetics,21 or due
to mechanical reasons such as large bone defects. There was
high quality evidence showing a lack of benefit in accelerating
healing for fresh fractures, thus it is unlikely that LIPUS would
improve outcomes in patients with non-union. Given the panel’s
judgment of an implausible benefit of LIPUS for patients with
non-union, the panel chose to make a strong recommendation
against LIPUS also for these patients.
Practical considerations
Patients with fracturesmay experience pain and limitedmobility,
particularly in the first two to three months. Driving and physical
activity are limited during the recovery period. Figure 2⇓
outlines the key practical issues for those considering LIPUS
as an adjunct therapy in the management of bone fractures.
Costs and resources
LIPUS does not represent an efficient use of health resources
for individuals or health funders, given its lack of benefit on
outcomes important to patients and its purchasing costs.
Healthcare organisations that currently pay for LIPUS may
reasonably choose to stop reimbursements based on best current
evidence and our strong recommendation against LIPUS.
Future research
It is unlikely that new trials will alter the evidence. Fracture
research should focus on other interventions that have a greater
probability to speed up healing, such as surgical application of
adjuvant biomaterials or extracorporeal shock wave therapy.22 23
Further trials of treatments for non-union fractures would be
better compared with operative stabilisation, with or without
autologous bone grafts. Research should also address
de-implementation strategies for the use of LIPUS for bone
healing.24
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How patients were involved in the creation of this article
Four people with lived experience of bone fractures, one of whom had used LIPUS, were full panel members, participated in the teleconferences
and email discussions, and met all authorship criteria. These panel members identified important outcomes and led the discussions about
values and preferences. Return to work or regular activities and pain were weighed as of higher importance for patients than radiographic
healing. The panel identified key practical issues including concerns with cost and access to LIPUS, as well as the burden of therapy. In
light of the lack of efficacy, one patient panel member remarked, and the others agreed, that discussing LIPUS would unnecessarily take
valuable time from the patient-clinician encounter, which is often already too short.
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Figures
Fig 1 Characteristics of patients and trials included in systematic review of LIPUS
Fig 2 Practical issues about use of LIPUS
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